DAMAGE TO THE CENTRAL NERVOUS SYSTEM IN COMMUNITY ACQUISITED PNEUMONIA IN CHILDREN
Abstract
Relevance. Community-acquired pneumonia (CAP) with complications is typical for respiratory diseases and occurs in up to 20% of children. In addition to respiratory failure, children with CAP often experience complications from the central nervous system (CNS). Such complications include toxic-metabolic syndrome, convulsive syndrome, hypoxic encephalopathy. Purpose of the study. Early diagnosis, prevention of complications and optimization of treatment of children with CAP with central nervous system and heart damage. Methods and research. Under observation were 48 children with CAP who were being treated at a multidisciplinary clinic of the Tashkent Medical Academy; 14 (29.16%) children had toxic-metabolic syndrome, 12 (25.00%) had pathological changes in the cardiovascular system. The levels of respiratory failure and saturation indicator were determined, an ultrasound examination of the brain, an ECG and general clinical and laboratory tests were performed. Research results. In 15 (31.25%) sick children, a severe course of VP, symptoms of III degree DN, saturation index ≤85.0%, 16.6% signs of hypoxia during an UTT study of the brain were revealed. 14 (29.16%) treated children had symptoms of damage to the nervous system 18 (37.5%), had pathological changes in the cardiovascular system 17 (35.41%) (decrease in the QRS complex 15 (31.25%), partial block of the right branch of the Hiss bundle 7 (14.58%) and 4 (8.33%) had a partial block of the left branch of the bundle Gissa. Conclusions. To optimize the early diagnosis and treatment of the acute phase of CAP, central nervous system and heart damage, it is necessary to conduct symptomatology of DN, radiography, ultrasonography, MSCT and ECG of the lungs, determine and correct the O2 saturation index, and consult a pediatric neurologist and cardiologist.
About the Authors
List of references
Meyer Sauteur PM, Beeton ML, on behalf of the ESGMAC and the ESGMAC Mycoplasma pneumoniae Surveillance (MAPS) study group. Mycoplasma pneumoniae: delayed re-emergence after COVID-19 pan demic restrictions. Lancet Microbe. 2023;23:S2666-5247(2623)00344 00340. doi: 10.1016/S2666-5247(23)00344-0.
Youn YS, Lee KY. Mycoplasma pneumoniae pneumonia in children. Korean Journal of Pediatrics 2012; 55(2):42-7. ttps:doi:10.3345/kjp.2012.55.2.42
Karimdzhanov I.A., Madaminova M.Sh., Iskanova G.Kh., Gazieva A.S., Togaev M.Q. Diagnosis and treatment of community-acquired pneumonia in children. Child health, 2024, T.19, N5, 2024, p.65-68
Danino D, Ben-Shimol S, Van Der Beek BA, Givon-Lavi N, Avni YS, et al. Decline in pneumococcal disease in young children du ring the coronavirus disease 2019 (COVID-19) pandemic in Israel as sociated with suppression of seasonal respiratory viruses, despite persis tent pneumococcal carriage: a prospective cohort study. Clin Infect Dis. 2022;75:e1154-e1164. doi: 10.1093/cid/ciab1014
Karimdzhanov IA, Iskanova GKh, Isroilova NA. Sequential therapy of community-acquired pneumonia in children. Child’s Health. 2014;3(54):70-73. doi: 10.22141/2224-0551.3.54.2014.76003.
Bielicki JA, Stohr W, Barratt S, Dunn D, Naufal N, et al. Effect of amoxicillin dose and treatment duration on the need for antibiotic re-treatment in children with community-acquired pneumonia: the CAP-IT randomized clinical trial. JAMA. 2021;326:1713-1724. doi: 10.1001/jama.2021.17843.
Kuitunen I, Jaaskelainen J, Korppi M, Renko M. Antibiotic treatment duration for community-acquired pneumonia in outpatient children in high-income countries — a systematic review and meta-analysis. Clin Infect Dis. 2023;76:e1123-e1128. doi: 10.1093/cid/ciac374.
Furman E.G., Balkunova Yu.N., Boyko M.Yu., Estemesova R.A. Ultrasound examination of the lungs in the diagnosis of pneumonia in children. Doctor.Ru. 2024;23(6):58–63. DOI: 10.31550/1727-2378-2024-23-6-58-63
Huang W, Xu X, Zhao W, Cheng Q. Refractory Mycoplasma pneu moniae in Children: A Systematic Review and Meta-analysis of Labora tory Features and Predictors. J Immunol Res. 2022 Jun 26;2022:9227838. doi: 10.1155/2022/9227838.
How to Cite

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.